The prognosis of fibrolamellar carcinoma versus conventional hepatocellular carcinoma: a study based on propensity score matching

References

• Kaczynski J, Gustavsson B, Hansson G, et al. Fibrolamellar hepatic carcinoma in an area with a low incidence of primary liver cancer: a retrospective study. Eur J Surg. 1996;162(5):367–371.
   PubMedGoogle Scholar
• El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803. doi: 10.1002/hep.20096.
   PubMed Web of Science ®Google Scholar
• Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91(2):168–186. doi: 10.1001/archpedi.1956.02060020170015.
   PubMedGoogle Scholar
• Pinna AD, Iwatsuki S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26(4):877–883. doi: 10.1002/hep.510260412.
   PubMed Web of Science ®Google Scholar
• Lin CC, Yang HM. Fibrolamellar carcinoma: a concise review. Arch Pathol Lab Med. 2018;142(9):1141–1145. doi: 10.5858/arpa.2017-0083-RS.
   PubMed Web of Science ®Google Scholar
• Njei B, Konjeti VR. Ditah I: prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis. Gastrointestinal Cancer Research. 2014;7(2):49–54.
   PubMedGoogle Scholar
• Eggert T, McGlynn KA, Duffy A, et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J. 2013;1(5):351–357. doi: 10.1177/2050640613501507.
   PubMed Web of Science ®Google Scholar
• McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. 1999;19(2):453–471. doi: 10.1148/radiographics.19.2.g99mr09453.
   PubMed Web of Science ®Google Scholar
• Collier NA, Weinbren K, Bloom SR, et al. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. 1984;1(8376):538–540. doi: 10.1016/s0140-6736(84)90934-6.
   PubMed Web of Science ®Google Scholar
• Wahab MA, El Hanafy E, El Nakeeb A, et al. Clinicopathological features and surgical outcome of patients with fibrolamellar hepatocellular carcinoma (experience with 22 patients over a 15-year period). World J Gastrointest Surg. 2017;9(2):61–67. doi: 10.4240/wjgs.v9.i2.61.
   PubMed Web of Science ®Google Scholar
• Lau CS, Mahendraraj K, Chamberlain RS. Hepatocellular carcinoma in the pediatric population: a population based clinical outcomes study involving 257 patients from the surveillance, epidemiology, and end result (SEER) database (1973–2011). HPB Surg. 2015;2015:670728. doi: 10.1155/2015/670728.
   PubMedGoogle Scholar
• McAteer JP, Goldin AB, Healey PJ, et al. Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr Transplant. 2013;17(8):744–750. doi: 10.1111/petr.12144.
   PubMed Web of Science ®Google Scholar
• Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106(6):1331–1338. doi: 10.1002/cncr.21703.
   PubMed Web of Science ®Google Scholar
• Kanai T, Takabayashi T, Kawano Y, et al. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol. 2004;34(6):346–351. doi: 10.1093/jjco/hyh050.
   PubMed Web of Science ®Google Scholar
• Simonsen K, Rode A, Nicoll A, et al. Vitamin B12 and its binding proteins in hepatocellular carcinoma and chronic liver diseases. Scand J Gastroenterol. 2014;49(9):1096–1102. doi: 10.3109/00365521.2014.921325.
   PubMed Web of Science ®Google Scholar
• Soreide O, Czerniak A, Bradpiece H, et al. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg. 1986;151(4):518–523. doi: 10.1016/0002-9610(86)90117-0.
   PubMed Web of Science ®Google Scholar
• McPeake JR, O’Grady JG, Zaman S, et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol. 1993;18(2):226–234. doi: 10.1016/s0168-8278(05)80250-8.
   PubMed Web of Science ®Google Scholar
• Wood WJ, Rawlings M, Evans H, et al. Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. Am J Surg. 1988;155(5):663–666. doi: 10.1016/s0002-9610(88)80139-9.
   PubMed Web of Science ®Google Scholar
• Kakar S, Burgart LJ, Batts KP, et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18(11):1417–1423. doi: 10.1038/modpathol.3800449.
   PubMed Web of Science ®Google Scholar
• Yamashita S, Vauthey JN, Kaseb AO, et al. Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg. 2016;20(10):1725–1731. doi: 10.1007/s11605-016-3216-x.
   PubMed Web of Science ®Google Scholar
• Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma–results and treatment recommendations from the childhood liver tumour strategy group (SIOPEL) experience. Eur J Cancer. 2013;49(12):2698–2704. doi: 10.1016/j.ejca.2013.04.012.
   PubMed Web of Science ®Google Scholar
• McDonald JD, Gupta S, Shindorf ML, et al. Elevated serum α-fetoprotein is associated with abbreviated survival for patients with fibrolamellar hepatocellular carcinoma who undergo a curative resection. Ann Surg Oncol. 2020;27(6):1900–1905. doi: 10.1245/s10434-019-08178-x.
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi: 10.1080/00273171.2011.568786.
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results (SEER) Program. Avaialble from: https://seer.cancer.gov/about/overview.html.
   Google Scholar
• Eggert T, McGlynn KA, Duffy A, et al. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000–10. Gut. 2013;62(11):1667–1668. doi: 10.1136/gutjnl-2013-305164.
   PubMed Web of Science ®Google Scholar
• Ramai D, Ofosu A, Lai JK, et al. Fibrolamellar hepatocellular carcinoma: a population-based observational study. Dig Dis Sci. 2021;66(1):308–314. doi: 10.1007/s10620-020-06135-3.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi: 10.3322/caac.21388.
   PubMed Web of Science ®Google Scholar
• Lunt M. Selecting an appropriate caliper can be essential for achieving good balance with propensity score matching. Am J Epidemiol. 2014;179(2):226–235. doi: 10.1093/aje/kwt212.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kim HJ, Lonjon G, et al. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7(1):16. doi: 10.21037/atm.2018.12.10.
   PubMed Web of Science ®Google Scholar
• Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. doi: 10.1016/S0140-6736(21)01374-X.
   PubMed Web of Science ®Google Scholar
• Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214(3):221–229. doi: 10.1097/00000658-199109000-00005.
   PubMed Web of Science ®Google Scholar
• Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228(4):479–490. doi: 10.1097/00000658-199810000-00005.
   PubMed Web of Science ®Google Scholar
• Epstein BE, Pajak TF, Haulk TL, et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. 1999;22(1):22–28. doi: 10.1097/00000421-199902000-00006.
   PubMed Web of Science ®Google Scholar
• Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21(3):421–427. doi: 10.1200/JCO.2003.10.103.
   PubMed Web of Science ®Google Scholar
• Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97(8):2006–2012. doi: 10.1002/cncr.11292.
   PubMed Web of Science ®Google Scholar
• Mayo SC, Mavros MN, Nathan H, et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014;218(2):196–205. doi: 10.1016/j.jamcollsurg.2013.10.011.
   PubMed Web of Science ®Google Scholar
• Atienza LG, Berger J, Mei X, et al. Liver transplantation for fibrolamellar hepatocellular carcinoma: a national perspective. J Surg Oncol. 2017;115(3):319–323. doi: 10.1002/jso.24515.
   PubMed Web of Science ®Google Scholar